First in Human Study of ALS-002200; Single Dose, Food Effect in Healthy Volunteers; Multiple Doses in Chronic Hepatitis C Genotype 1

Phase 1

Completed

• Conditions: Hepatitis C, Chronic
• Interventions: Drug: ALS-002200; Drug: Placebo

• Registration Number: NCT01590407
• Lead Sponsor: Alios Biopharma Inc.

Brief Summary

This randomized, double-blind, placebo-controlled, 3-part study will assess the safety, tolerability, and pharmacokinetics of orally administered ALS-002200 in healthy volunteers (HV) and subjects with chronic hepatitis C (CHC) genotype 1 infection.

Part 1 will assess single ascending dosing pharmacokinetics and safety in HV. Part 2 will assess food effects on pharmacokinetics in HV. Part 3 will assess multiple ascending dosing pharmacokinetics and safety in subjects with CHC genotype 1 infection.

Detailed Description

Not available

Study Timeline

• Study Start: 2011-12-31
• Study First Submitted: 2012-03-12
• Study First Submitted QC: 2012-05-02
• Study First Posted: 2012-05-03
• Primary Completion: 2013-02-28
• Study Completion: 2013-02-28
• Status Verified: 2017-10
• Last Update Submitted: 2017-10-27
• Last Update Posted: 2017-10-31

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 71

Inclusion Criteria

• Subject has provided written consent.
• In the investigator's opinion, the subject is able to understand and comply with protocol requirements, instructions, and protocol stated restrictions and is likely to complete the study as planned.
• Subject is in good health as deemed by the investigator.
• Creatinine clearance of greater than 50 mL/min (Cockcroft-Gault)
• Male or female, 18-55 years of age for HV and 18-65 years of age for subjects with CHC.
• Body mass index (BMI) 18-32 kg/m2 inclusive for HV and 18-36 kg/m2 for subjects with CHC, minimum weight 50 kg in both populations.
• A female is eligible to participate in this study if she is of non childbearing potential.
• If male, subject is surgically sterile or practicing specific forms of birth control.

Additional inclusion criteria for subjects with CHC genotype 1 infection:

• Positive HCV antibody and a positive HCV RNA at screening.

• Documentation of CHC infection for greater than 6 months at screening

• CHC genotype 1 infection at screening

• HCV RNA viral load ≥ 105 and ≤108 IU/mL using a sensitive quantitative assay.

• Liver biopsy within two years or Fibroscan evaluation within 6 months prior to screening that clearly excludes cirrhosis. Fibroscan liver stiffness score must be < 12 kPa.

• Absence of hepatocellular carcinoma as indicated by an ultrasound scan conducted during screening

• No prior treatment for CHC

• Absence of history of clinical hepatic decompensation.

• Laboratory values include:

  • Prothrombin time < 1.5x ULN
  • Platelets > 120,000/mm3
  • Albumin > 3.5 g/dL, bilirubin < 1.5 mg/dL at screening (subjects with documented Gilbert's disease allowed).
  • Serum alanine aminotransferase (ALT) concentration < 5 x ULN
  • Alpha Fetoprotein (AFP) concentrations ≤ ULN. If AFP is ≥ ULN, absence of a hepatic mass must be demonstrated by ultrasound within the screening period.

Exclusion Criteria

• Clinically significant cardiovascular, respiratory, renal, gastrointestinal, hematologic, neurologic, thyroid, or any uncontrolled medical illness or psychiatric disorder.

• Positive test for HAV IgM, HBsAg, HCV Ab (HV only), or HIV Ab.

• Abnormal screening laboratory results that are considered clinically significant by the investigator.

• Drug allergy such as, but not limited to, sulfonamides and penicillins, including those experienced in previous trials with experimental drugs.

• Participation in an investigational drug trial or having received an investigational vaccine within 30 days or 5 half lives (whichever is longer) prior to study medication.

• Clinically significant blood loss or elective blood donation of significant volume.

• For healthy subjects, history of regular use of tobacco.

• The subject has a positive pre-study drug screen.

• Laboratory abnormalities including:

  • Thyroid Stimulating Hormone (TSH) > ULN
  • Hematocrit < 34 %
  • White blood cell counts < 3,500/mm3

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
ALS-002200	ALS-002200	-
Placebo	Placebo	-

Primary Outcome Measures

Name	Time	Method
Number of Participants with Adverse Events as a Measure of Safety and Tolerability	up to Day 31	data points measured include patient reported adverse events, physical exams, vital signs, 12-lead ECGs and clinical lab results

Secondary Outcome Measures

Name	Time	Method
Cmax	pre-dose and 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 240 hours post dose
AUC	pre-dose and 0.25, 0.5, 1, 2, 3,4, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 240 hours post dose
HCV ribonucleic acid (RNA) viral load reduction	Baseline to Day 31
Amino Acid Changes in HCV polymerase NS5b	Baseline up to Month 6	Comparison of baseline with on-treatment or post-treatment Hepatitis C virus (HCV) NS5B RNA sequence

Trial Locations

Locations (2)

Arensia; 🇷🇴 Bucharest, Romania

Biotrial; 🇫🇷 Paris, France